Clinical Trials
29 trialsCord Blood Transplantation in Children and Young Adults With Blood Cancer
Memorial Sloan Kettering Cancer Center
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
City of Hope Medical Center
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
University of Pittsburgh
CY-MET-RIC
Nantes University Hospital
Optimizing PTCy Dose and Timing
National Institutes of Health Clinical Center (CC)
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
Thomas Jefferson University
IS-free Treg HaploHCT
Dana-Farber Cancer Institute
Haplo Peripheral Blood Sct In GVHD Prevention
Massachusetts General Hospital
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
City of Hope Medical Center
VICTORY
Melbourne Health
HLA
University of Liege
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
H. Lee Moffitt Cancer Center and Research Institute
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
M.D. Anderson Cancer Center
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
M.D. Anderson Cancer Center
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
Thomas Jefferson University
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
M.D. Anderson Cancer Center
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
Massachusetts General Hospital
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
M.D. Anderson Cancer Center
HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
University of Chicago
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
Ann & Robert H Lurie Children's Hospital of Chicago
T&B Depletion Non Malignant
Bambino Gesù Hospital and Research Institute
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Cellular Therapy With Cord Blood Cells
M.D. Anderson Cancer Center
Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies
M.D. Anderson Cancer Center